Cognition Therapeutics Latest Episode of “Conversations” Podcast Features Biomarker Experts from Gothenburg University, Emory and Amsterdam UMC
23 5월 2023 - 8:30PM
Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or
“Cognition”) has released its fifth “Conversations” video podcast,
a review and interactive discussion of Cognition’s CT1812 biomarker
results presented at AD/PD™ 2023, the Alzheimer's & Parkinson's
Diseases Conference. Cognition VP of research, Mary Hamby, PhD
presents findings from an unbiased proteomic analysis of combined
datasets from the first cohort of the Phase 2 SHINE study and the
completed Phase 1b SPARC study, both conducted in mild-to-moderate
Alzheimer's disease patients and similarly treated with either
CT1812 or placebo.
This meta-analysis revealed that CT1812 treatment was associated
with statistically significant changes in biomarkers associated
with:
- synaptic function,
- amyloid biology,
- and neuroinflammation.
Importantly, these changes in key biomarkers were replicated
across studies, and had similar directionality and degree of
change.
In this conversation, Dr. Charlotte Teunissen moderates a
discussion on interpretation of these findings and their relevance
to the CT1812 mechanism of action with two leading experts in
biomarker development.
Episode 5: “Exploring the Effects of CT1812 on Alzheimer’s
Disease Processes: Proteomics and Pathways of Neurodegeneration”
features:
- Charlotte Teunissen, PhD - Professor of Clinical Neurochemistry
at Amsterdam University Medical Center
- Nicholas Seyfried, PhD - Professor of Biochemistry and
Neurology at Emory University School of Medicine and Director of
the Emory Integrated Proteomics Core
- Henrik Zetterberg, MD, PhD - Professor of Neuroscience at
Gothenburg University and Group Leader of the UK Dementia Research
Institute
Cognition Therapeutics welcomes comments, questions and feedback
on this and other Conversations episodes which may be submitted at
conversations@cogrx.com. We’d love to hear your thoughts!
About Cognition Therapeutics, Inc.Cognition
Therapeutics, Inc. is a clinical-stage biopharmaceutical company
engaged in the discovery and development of innovative, small
molecule therapeutics targeting age-related degenerative disorders
of the central nervous system and retina. We are currently
investigating our lead candidate CT1812 in clinical programs in
Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry
age-related macular degeneration (dry AMD). We believe CT1812 and
our pipeline of σ-2 receptor modulators can regulate pathways that
are impaired in these diseases. We believe that targeting the σ-2
receptor with CT1812 represents a mechanism functionally distinct
from other current approaches in clinical development for the
treatment of degenerative diseases. More about Cognition
Therapeutics and its pipeline can be found
at https://cogrx.com
Health Care Disclaimer Our podcast series does
not constitute the practice of medical advice, diagnosis or
treatment. Always talk to your health care provider for diagnosis
and treatment, including your specific medical needs. If you have
or suspect that you have a medical problem or condition, please
contact a qualified health care professional immediately.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. All statements
contained in this press release, other than statements of
historical facts or statements that relate to present facts or
current conditions, including but not limited to, statements
regarding our product candidates, any expected or implied benefits
or results, including that initial clinical results observed with
respect to CT1812 will be replicated in later trials and our
clinical development plans, including statements regarding our
clinical studies of CT1812 and any analyses of the results
therefrom, are forward-looking statements. These statements,
including statements relating to the timing and expected results of
our clinical trials, involve known and unknown risks, uncertainties
and other important factors that may cause our actual results,
performance, or achievements to be materially different from any
future results, performance, or achievements expressed or implied
by the forward-looking statements. In some cases, you can identify
forward-looking statements by terms such as “may,” might,” “will,”
“should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,”
“intend,” “target,” “project,” “contemplate,” “believe,”
“estimate,” “predict,” “forecast,” “potential” or “continue” or the
negative of these terms or other similar expressions. We have based
these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our business, financial
condition, and results of operations. These forward-looking
statements speak only as of the date of this press release and are
subject to a number of risks, uncertainties and assumptions, some
of which cannot be predicted or quantified and some of which are
beyond our control. Factors that may cause actual results to differ
materially from current expectations include, but are not limited
to: competition; our ability to secure new (and retain existing)
grant funding; our ability to grow and manage growth, maintain
relationships with suppliers and retain our management and key
employees; our ability to successfully advance our current and
future product candidates through development activities,
preclinical studies and clinical trials and costs related thereto;
uncertainties inherent in the results of preliminary data and
pre-clinical studies being predictive of the results of clinical
trials; the timing, scope and likelihood of regulatory filings and
approvals, including regulatory approval of our product candidates;
changes in applicable laws or regulations; the possibility that the
we may be adversely affected by other economic, business or
competitive factors, including ongoing economic uncertainty; our
estimates of expenses and profitability; the evolution of the
markets in which we compete; our ability to implement our strategic
initiatives and continue to innovate our existing products; our
ability to defend our intellectual property; the impact of the
COVID-19 pandemic on our business, supply chain and labor force;
and the risks and uncertainties described in the “Risk Factors”
section of our annual and quarterly reports filed with the
Securities & Exchange Commission. These risks are not
exhaustive and we face both known and unknown risks. You should not
rely on these forward-looking statements as predictions of future
events. The events and circumstances reflected in our
forward-looking statements may not be achieved or occur, and actual
results could differ materially from those projected in the
forward-looking statements. Moreover, we operate in a dynamic
industry and economy. New risk factors and uncertainties may emerge
from time to time, and it is not possible for management to predict
all risk factors and uncertainties that we may face. Except as
required by applicable law, we do not plan to publicly update or
revise any forward-looking statements contained herein, whether as
a result of any new information, future events, changed
circumstances or otherwise.
Contact Information:Cognition Therapeutics,
Inc. info@cogrx.com
Bill Borden (media) Tiberend Strategic Advisors, Inc.
bborden@tiberend.com
Daniel Kontoh-Boateng (investors) Tiberend Strategic
Advisors, Inc. dboateng@tiberend.com
Cognition Therapeutics (NASDAQ:CGTX)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Cognition Therapeutics (NASDAQ:CGTX)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024